Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aura Biosciences, Inc. - Common Stock (NQ:AURA)

6.745 -0.055 (-0.81%)
Streaming Delayed Price Updated: 1:19 PM EDT, Aug 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aura Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022
From Aura Biosciences, Inc.
Via Business Wire
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial... 
Via Benzinga
JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer"
 
Via Benzinga
Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer
 
Via Benzinga
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022
From Aura Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga
Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress
From Aura Biosciences Inc.
Via Business Wire
Bed Bath & Beyond, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
  Bed Bath & Beyond Inc. (NASDAQ: BBBY) fell 23.3% to $17.71 following a Form 144 filing by RC Ventures, which suggested the firm proposed to sell 7.78 million common shares and certain call options.... 
Via Benzinga
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66. 
Via Benzinga
Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference
From Aura Biosciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022
Upgrades 
Via Benzinga
Aura Biosciences' Stock Gains As FDA Grants Fast Track Status To Bladder Cancer Drug
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Aura Biosciences’ (NASDAQ: AURA) belzupacap sarotalocan (AU-011) for the treatment of Non-Muscle Invasive Bladder... 
Via Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
From Aura Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.3% to $1.03 during Wednesday's after-market session. The company's market cap stands at $33.2 million. 
Via Benzinga
Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma
From Aura Biosciences Inc.
Via Business Wire
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)
From Aura Biosciences Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.